Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fe… Read more
Cumberland Pharmaceuticals Inc (CPIX) - Net Assets
Latest net assets as of September 2025: $25.80 Million USD
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has net assets worth $25.80 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.90 Million) and total liabilities ($40.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.80 Million |
| % of Total Assets | 39.15% |
| Annual Growth Rate | 7.0% |
| 5-Year Change | -51.9% |
| 10-Year Change | -70.65% |
| Growth Volatility | 73.1 |
Cumberland Pharmaceuticals Inc - Net Assets Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cumberland Pharmaceuticals Inc (2005–2024)
The table below shows the annual net assets of Cumberland Pharmaceuticals Inc from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.55 Million | -22.95% |
| 2023-12-31 | $29.26 Million | -18.66% |
| 2022-12-31 | $35.97 Million | -15.56% |
| 2021-12-31 | $42.60 Million | -9.11% |
| 2020-12-31 | $46.87 Million | -8.24% |
| 2019-12-31 | $51.09 Million | -8.07% |
| 2018-12-31 | $55.57 Million | -13.06% |
| 2017-12-31 | $63.92 Million | -12.58% |
| 2016-12-31 | $73.12 Million | -4.82% |
| 2015-12-31 | $76.82 Million | -4.87% |
| 2014-12-31 | $80.75 Million | +1.84% |
| 2013-12-31 | $79.29 Million | -7.33% |
| 2012-12-31 | $85.57 Million | +3.30% |
| 2011-12-31 | $82.84 Million | +6.59% |
| 2010-12-31 | $77.72 Million | +7.61% |
| 2009-12-31 | $72.22 Million | +311.40% |
| 2008-12-31 | $17.55 Million | +4.83% |
| 2007-12-31 | $16.75 Million | +50.52% |
| 2006-12-31 | $11.13 Million | +78.48% |
| 2005-12-31 | $6.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cumberland Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1220355600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $46.82 Million | 204.88% |
| Total Equity | $22.85 Million | 100.00% |
Cumberland Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daesung Holdin
KO:016710
|
$26.28 Million |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
$26.29 Million |
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
$26.29 Million |
|
Offerpad Solutions Inc
NYSE:OPAD
|
$26.29 Million |
|
Osangjaiel Co. Ltd
KQ:053980
|
$26.27 Million |
|
HERITAGE GLOBAL DL-007
F:LGC
|
$26.26 Million |
|
Manaksia Coated Metals & Industries Limited
NSE:MANAKCOAT
|
$26.24 Million |
|
Thai Reinsurance Public Company Limited
BK:THRE
|
$26.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cumberland Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,603,441 to 22,853,494, a change of -6,749,947 (-22.8%).
- Net loss of 6,479,770 reduced equity.
- Share repurchases of 579,049 reduced equity.
- Other factors increased equity by 308,872.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.48 Million | -28.35% |
| Share Repurchases | $579.05K | -2.53% |
| Other Changes | $308.87K | +1.35% |
| Total Change | $- | -22.80% |
Book Value vs Market Value Analysis
This analysis compares Cumberland Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.77x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.39 | $3.01 | x |
| 2006-12-31 | $0.68 | $3.01 | x |
| 2007-12-31 | $1.01 | $3.01 | x |
| 2008-12-31 | $1.06 | $3.01 | x |
| 2009-12-31 | $3.96 | $3.01 | x |
| 2010-12-31 | $3.69 | $3.01 | x |
| 2011-12-31 | $4.03 | $3.01 | x |
| 2012-12-31 | $4.33 | $3.01 | x |
| 2013-12-31 | $4.33 | $3.01 | x |
| 2014-12-31 | $4.51 | $3.01 | x |
| 2015-12-31 | $4.50 | $3.01 | x |
| 2016-12-31 | $4.51 | $3.01 | x |
| 2017-12-31 | $4.03 | $3.01 | x |
| 2018-12-31 | $3.58 | $3.01 | x |
| 2019-12-31 | $3.32 | $3.01 | x |
| 2020-12-31 | $3.10 | $3.01 | x |
| 2021-12-31 | $2.87 | $3.01 | x |
| 2022-12-31 | $2.49 | $3.01 | x |
| 2023-12-31 | $2.07 | $3.01 | x |
| 2024-12-31 | $1.63 | $3.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cumberland Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.11%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 3.31x
- Recent ROE (-28.35%) is below the historical average (1.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 31.35% | 18.28% | 1.05x | 1.63x | $1.33 Million |
| 2006 | 39.59% | 24.72% | 0.67x | 2.38x | $3.29 Million |
| 2007 | 24.15% | 14.41% | 0.97x | 1.73x | $2.37 Million |
| 2008 | 27.15% | 13.59% | 1.13x | 1.77x | $3.01 Million |
| 2009 | 4.28% | 7.10% | 0.42x | 1.44x | $-4.13 Million |
| 2010 | 3.16% | 5.36% | 0.50x | 1.18x | $-5.32 Million |
| 2011 | 6.82% | 11.06% | 0.54x | 1.15x | $-2.64 Million |
| 2012 | 6.82% | 11.96% | 0.50x | 1.15x | $-2.73 Million |
| 2013 | -2.65% | -6.57% | 0.37x | 1.10x | $-10.05 Million |
| 2014 | 3.00% | 6.57% | 0.39x | 1.18x | $-5.65 Million |
| 2015 | 0.95% | 2.18% | 0.36x | 1.20x | $-6.96 Million |
| 2016 | -1.29% | -2.86% | 0.35x | 1.28x | $-8.27 Million |
| 2017 | -12.44% | -19.39% | 0.44x | 1.45x | $-14.39 Million |
| 2018 | -12.47% | -17.09% | 0.36x | 2.02x | $-12.55 Million |
| 2019 | -6.92% | -10.29% | 0.33x | 2.05x | $-8.65 Million |
| 2020 | -7.11% | -8.92% | 0.39x | 2.05x | $-8.04 Million |
| 2021 | -8.19% | -9.75% | 0.43x | 1.97x | $-7.79 Million |
| 2022 | -15.36% | -13.26% | 0.45x | 2.56x | $-9.20 Million |
| 2023 | -21.21% | -15.88% | 0.48x | 2.76x | $-9.24 Million |
| 2024 | -28.35% | -17.11% | 0.50x | 3.31x | $-8.77 Million |
Industry Comparison
This section compares Cumberland Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc (CPIX) | $25.80 Million | 31.35% | 1.55x | $26.28 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |